Real-world analysis of fingolimod versus teriflunomide in relapsing–remitting multiple sclerosis

Takeaway

  • People with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod experienced better relapse control versus those treated with teriflunomide, but disability progression was similar in the two treatment groups.

Why this matters

    In the absence of head-to-head trials comparing oral drugs for treatment of MS, real-world comparative data can help physicians and patients make informed, individualized treatment decisions.